A few studies have so far investigated the potential clinical application of newer molecular methods, namely ddPCR [27,48,59,61] and NGS [41,46,56,60,62,63,65,68,69,73], to monitor MRD in NPM1-mutated AML patients. This evidence concerns the gene NPM1 and acute myeloid leukemia.